Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate

References

• Anderson DW Ellenberg JH Leventhal CM Revised estimate of the prevalence of multiple sclerosis in the United States Ann Neurol 1992 31 3 333 336 1637140
   PubMed Web of Science ®Google Scholar
• Frohman EM Racke MK Raine CS Multiple sclerosis – the plaque and its pathogenesis N Engl J Med 2006 354 9 942 955 16510748
   PubMed Web of Science ®Google Scholar
• Arnason BG Relevance of experimental allergic encephalomyelitis to multiple sclerosis Neurol Clin 1983 1 3 765 782 6209540
   PubMedGoogle Scholar
• Sadovnick AD Ebers GC Epidemiology of multiple sclerosis: a critical overview Can J Neurol Sci 1993 20 1 17 29 8467424
   PubMed Web of Science ®Google Scholar
• [No authors listed] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 1993 43 4 655 661 8469318
   PubMed Web of Science ®Google Scholar
• Jacobs LD Cookfair DL Rudick RA Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 1996 39 3 285 294 8602746
   PubMed Web of Science ®Google Scholar
• Johnson KP Brooks BR Cohen JA Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 1995 45 7 1268 1276 7617181
   PubMed Web of Science ®Google Scholar
• Millefiorini E Gasperini C Pozzilli C Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome J Neurol 1997 244 3 153 159 9050955
   PubMed Web of Science ®Google Scholar
• Polman CH O’Connor PW Havrdova E A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 2006 354 9 899 910 16510744
   PubMed Web of Science ®Google Scholar
• Kappos L Radue EW O’Connor P A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 2010 362 5 387 401 20089952
   PubMed Web of Science ®Google Scholar
• O’Connor P Wolinsky JS Confavreux C Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 2011 365 14 1293 1303 21991951
   PubMed Web of Science ®Google Scholar
• Gold R Kappos L Arnold DL Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 2012 367 12 1098 1107 22992073
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK Tyler KL Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 2005 353 4 369 374 15947079
   PubMed Web of Science ®Google Scholar
• Langer-Gould A Atlas SW Green AJ Bollen AW Pelletier D Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 2005 353 4 375 381 15947078
   PubMed Web of Science ®Google Scholar
• Van Assche G Van Ranst M Sciot R Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease N Engl J Med 2005 353 4 362 368 15947080
   PubMed Web of Science ®Google Scholar
• Altmeyer PJ Matthes U Pawlak F Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients J Am Acad Dermatol 1994 30 6 977 981 8188891
   PubMed Web of Science ®Google Scholar
• Kappos L Gold R Miller DH Haghikia A Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 2009 373 9672 1340 1340 19376451
   PubMed Web of Science ®Google Scholar
• Schimrigk S Brune N Hellwig K Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study Eur J Neurol 2006 13 6 604 610 16796584
   PubMed Web of Science ®Google Scholar
• Ghoreschi K Bruck J Kellerer C Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells J Exp Med 2011 208 11 2291 2303 21987655
   PubMed Web of Science ®Google Scholar
• Peng H Guerau-de-Arellano M Mehta VB Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling J Biol Chem 2012 287 33 28017 28026 22733812
   PubMed Web of Science ®Google Scholar
• Gocke AR Cravens PD Ben LH T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity J Immunol 2007 178 3 1341 1348 17237380
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE Rocchini AE Choy J Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes Immunity 2004 21 5 719 731 15539157
   PubMed Web of Science ®Google Scholar
• Yang Y Weiner J Liu Y T-bet is essential for encephalitogenicity of both Th1 and Th17 cells J Exp Med 2009 206 7 1549 1564 19546248
   PubMed Web of Science ®Google Scholar
• McDonald AH Swanborg RH Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis J Immunol 1988 140 4 1132 1138 2963860
   PubMed Web of Science ®Google Scholar
• Ando DG Clayton J Kono D Urban JL Sercarz EE Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype Cell Immunol 1989 124 1 132 143 2478300
   PubMed Web of Science ®Google Scholar
• Waldburger KE Hastings RC Schaub RG Goldman SJ Leonard JP Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms Am J Pathol 1996 148 2 375 382 8579100
   PubMed Web of Science ®Google Scholar
• Yura M Takahashi I Serada M Role of MOG-stimulated Th1 type “light up” (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE) J Autoimmun 2001 17 1 17 25 11488634
   PubMed Web of Science ®Google Scholar
• Olsson T Zhi WW Hojeberg B Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma J Clin Invest 1990 86 3 981 985 1697609
   PubMed Web of Science ®Google Scholar
• Sun JB Olsson T Wang WZ Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls Eur J Immunol 1991 21 6 1461 1468 1710567
   PubMed Web of Science ®Google Scholar
• Voskuhl RR Martin R Bergman C Dalal M Ruddle NH McFarland HF T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes Autoimmunity 1993 15 2 137 143 7692995
   PubMed Web of Science ®Google Scholar
• Pelfrey CM Rudick RA Cotleur AC Lee JC Tary-Lehmann M Lehmann PV Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production J Immunol 2000 165 3 1641 1651 10903775
   PubMed Web of Science ®Google Scholar
• Ferber IA Brocke S Taylor-Edwards C Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE) J Immunol 1996 156 1 5 7 8598493
   PubMed Web of Science ®Google Scholar
• Willenborg DO Fordham S Bernard CC Cowden WB Ramshaw IA IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis J Immunol 1996 157 8 3223 3227 8871615
   PubMed Web of Science ®Google Scholar
• Heremans H Dillen C Groenen M Martens E Billiau A Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma Eur J Immunol 1996 26 10 2393 2398 8898951
   PubMed Web of Science ®Google Scholar
• Bielekova B Goodwin B Richert N Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat Med 2000 6 10 1167 1175 11017150
   PubMed Web of Science ®Google Scholar
• Lublin FD Knobler RL Kalman B Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis Autoimmunity 1993 16 4 267 274 7517706
   PubMed Web of Science ®Google Scholar
• Chu CQ Wittmer S Dalton DK Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis J Exp Med 2000 192 1 123 128 10880533
   PubMed Web of Science ®Google Scholar
• Racke MK Burnett D Pak SH Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course J Immunol 1995 154 1 450 458 7527821
   PubMed Web of Science ®Google Scholar
• Racke MK Bonomo A Scott DE Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease J Exp Med 1994 180 5 1961 1966 7525845
   PubMed Web of Science ®Google Scholar
• Chitnis T Najafian N Benou C Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis J Clin Invest 2001 108 5 739 747 11544280
   PubMed Web of Science ®Google Scholar
• Bettelli E Sullivan B Szabo SJ Sobel RA Glimcher LH Kuchroo VK Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis J Exp Med 2004 200 1 79 87 15238607
   PubMed Web of Science ®Google Scholar
• Nath N Prasad R Giri S Singh AK Singh I T-bet is essential for the progression of experimental autoimmune encephalomyelitis Immunology 2006 118 3 384 391 16827899
   PubMed Web of Science ®Google Scholar
• Langrish CL Chen Y Blumenschein WM IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J Exp Med 2005 201 2 233 240 15657292
   PubMed Web of Science ®Google Scholar
• Lock C Hermans G Pedotti R Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat Med 2002 8 5 500 508 11984595
   PubMed Web of Science ®Google Scholar
• Lees JR Iwakura Y Russell JH Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines J Immunol 2008 180 12 8066 8072 18523270
   PubMed Web of Science ®Google Scholar
• Komiyama Y Nakae S Matsuki T IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis J Immunol 2006 177 1 566 573 16785554
   PubMed Web of Science ®Google Scholar
• Haak S Croxford AL Kreymborg K IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice J Clin Invest 2009 119 1 61 69 19075395
   PubMed Web of Science ®Google Scholar
• de Jong R Bezemer AC Zomerdijk TP van de Pouw-Kraan T Ottenhoff TH Nibbering PH Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate Eur J Immunol 1996 26 9 2067 2074 8814248
   PubMed Web of Science ®Google Scholar
• Ghoreschi K Mrowietz U Rocken M A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses J Mol Med (Berl) 2003 81 8 471 480 12879154
   PubMed Web of Science ®Google Scholar
• Loewe R Pillinger M de Martin R Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner J Invest Dermatol 2001 117 6 1363 1368 11886496
   PubMed Web of Science ®Google Scholar
• Schilling S Goelz S Linker R Luehder F Gold R Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration Clin Exp Immunol 2006 145 1 101 107 16792679
   PubMed Web of Science ®Google Scholar
• Linker RA Lee DH Ryan S Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 2011 134 Pt 3 678 692 21354971
   PubMed Web of Science ®Google Scholar
• Chen H Assmann JC Krenz A Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE J Clin Invest 2014 124 5 2188 2192 24691444
   PubMed Web of Science ®Google Scholar
• Milenkovic M Arsenovic-Ranin N Vucicevic D Bufan B Jancic I Stojic-Vukanic Z Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis Arch Med Res 2008 39 7 639 646 18760191
   PubMed Web of Science ®Google Scholar
• Sean RD Korner H Strickland DH Lemckert FA Pollard JD Sedgwick JD Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice J Exp Med 1998 187 9 1517 1528 9565643
   PubMed Web of Science ®Google Scholar
• Kroenke MA Carlson TJ Andjelkovic AV Segal BM IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition J Exp Med 2008 205 7 1535 1541 18573909
   PubMed Web of Science ®Google Scholar
• Johnson JA Johnson DA Kraft AD The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration Ann N Y Acad Sci 2008 1147 61 69 19076431
   PubMed Web of Science ®Google Scholar
• Schreibelt G van Horssen J van Rossum S Dijkstra CD Drukarch B de Vries HE Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology Brain Res Rev 2007 56 2 322 330 17761296
   PubMedGoogle Scholar
• van Muiswinkel FL Kuiperij HB The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders Curr Drug Targets CNS Neurol Disord 2005 4 3 267 281 15975029
   PubMedGoogle Scholar
• Franco R Schoneveld OJ Pappa A Panayiotidis MI The central role of glutathione in the pathophysiology of human diseases Arch Physiol Biochem 2007 113 4–5 234 258 18158646
   PubMedGoogle Scholar
• Wu G Fang YZ Yang S Lupton JR Turner ND Glutathione metabolism and its implications for health J Nutr 2004 134 3 489 492 14988435
   PubMed Web of Science ®Google Scholar
• Kapturczak MH Wasserfall C Brusko T Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse Am J Pathol 2004 165 3 1045 1053 15331427
   PubMed Web of Science ®Google Scholar
• Hu CM Lin HH Chiang MT Chang PF Chau LY Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice Diabetes 2007 56 5 1240 1247 17303808
   PubMed Web of Science ®Google Scholar
• Benallaoua M Francois M Batteux F Pharmacologic induction of heme oxygenase 1 reduces acute inflammatory arthritis in mice Arthritis Rheum 2007 56 8 2585 2594 17665394
   PubMed Web of Science ®Google Scholar
• Takeda Y Takeno M Iwasaki M Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody Clin Exp Immunol 2004 138 2 237 244 15498032
   PubMed Web of Science ®Google Scholar
• Rueda B Oliver J Robledo G HO-1 promoter polymorphism associated with rheumatoid arthritis Arthritis Rheum 2007 56 12 3953 3958 18050210
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y Melamed E Offen D The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy J Neurol 2004 251 3 261 268 15015004
   PubMed Web of Science ®Google Scholar
• Liu Y Liu J Tetzlaff W Paty DW Cynader MS Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis Free Radic Biol Med 2006 40 6 960 967 16540391
   PubMed Web of Science ®Google Scholar
• Tajouri L Mellick AS Ashton KJ Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis Brain Res Mol Brain Res 2003 119 2 170 183 14625084
   PubMedGoogle Scholar
• Calabrese V Scapagnini G Ravagna A Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine Neurochem Res 2003 28 9 1321 1328 12938853
   PubMed Web of Science ®Google Scholar
• Calvani M Arrigoni-Martelli E Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion Int J Tissue React 1999 21 1 1 6 10463134
   PubMedGoogle Scholar
• Guy J Ellis EA Hope GM Rao NA Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis Arch Ophthalmol 1989 107 9 1359 1363 2783067
   PubMedGoogle Scholar
• Liu Y Zhu B Luo L Li P Paty DW Cynader MS Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis Neuroreport 2001 12 9 1841 1845 11435909
   PubMed Web of Science ®Google Scholar
• Mehindate K Sahlas DJ Frankel D Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis J Neurochem 2001 77 5 1386 1395 11389189
   PubMed Web of Science ®Google Scholar
• Chora AA Fontoura P Cunha A Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation J Clin Invest 2007 117 2 438 447 17256058
   PubMed Web of Science ®Google Scholar
• Kalinin S Polak PE Lin SX Dimethyl fumarate regulates histone deacetylase expression in astrocytes J Neuroimmunol 2013 263 1–2 13 19 23916696
   PubMed Web of Science ®Google Scholar
• Pitt D Werner P Raine CS Glutamate excitotoxicity in a model of multiple sclerosis Nat Med 2000 6 1 67 70 10613826
   PubMed Web of Science ®Google Scholar
• Smith T Groom A Zhu B Turski L Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat Med 2000 6 1 62 66 10613825
   PubMed Web of Science ®Google Scholar
• Kanwar JR Kanwar RK Krissansen GW Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis Brain 2004 127 Pt 6 1313 1331 15130951
   PubMed Web of Science ®Google Scholar
• Werner P Pitt D Raine CS Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage Ann Neurol 2001 50 2 169 180 11506399
   PubMed Web of Science ®Google Scholar
• Srinivasan R Sailasuta N Hurd R Nelson S Pelletier D Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T Brain 2005 128 Pt 5 1016 1025 15758036
   PubMed Web of Science ®Google Scholar
• Lukashev M Zeng W Goelz S Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities Mult Scler 2007 13 Suppl S149 S149
   Google Scholar
• Fox RJ Miller DH Phillips JT Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 2012 367 12 1087 1097 22992072
   PubMed Web of Science ®Google Scholar
• Tecfidera^® Full prescribing information Dimethyl fumarate package insert Research Triangle Park, NC, USA Biogen Idec 2013 Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151 Accessed June 9, 2014
   Google Scholar
• Sweetser MT Dawson KT Bozic C Manufacturer’s response to case reports of PML N Engl J Med 2013 368 17 1659 1661 23614605
   PubMed Web of Science ®Google Scholar
• Ermis U Weis J Schulz JB PML in a patient treated with fumaric acid N Engl J Med 2013 368 17 1657 1658 23614603
   PubMed Web of Science ®Google Scholar
• van Oosten B Killestein J Barkhof F Polman CH Wattjes MP PML in a patient treated with dimethyl fumarate from a compounding pharmacy N Engl J Med 2013 368 17 1658 1659 23614604
   PubMed Web of Science ®Google Scholar
• Hutchinson M Fox RJ Havrdova E Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison Curr Med Res Opin 2014 30 4 613 627 24195574
   PubMed Web of Science ®Google Scholar
• Ratchford JN Costello K Reich DS Calabresi PA Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod Neurology 2012 79 19 2002 2004 23035072
   PubMed Web of Science ®Google Scholar
• Uccelli A Ginocchio F Mancardi GL Bassetti M Primary varicella zoster infection associated with fingolimod treatment Neurology 2011 76 11 1023 1024 21403115
   PubMed Web of Science ®Google Scholar
• Nicholas JA Racke MK Imitola J Boster AL First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks Ther Adv Chronic Dis 2014 5 2 62 68 24587891
   PubMedGoogle Scholar
• Kappos L Radue EW O’Connor P A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 2010 362 5 387 401 20089952
   PubMed Web of Science ®Google Scholar
• Coyle PK Multiple sclerosis in pregnancy Continuum (Minneap Minn) 2014 20 1 Neurology of Pregnancy 42 59 24492810
   PubMedGoogle Scholar
• O’Connor P Wolinsky JS Confavreux C Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 2011 365 14 1293 1303 21991951
   PubMed Web of Science ®Google Scholar
• Polman CH Uitdehaag BM New and emerging treatment options for multiple sclerosis Lancet Neurol 2003 2 9 563 566 12941579
   PubMed Web of Science ®Google Scholar
• Aubagio^® (teriflunomide) package insert Cambridge, MA, USA Genzyme Corporation 2012 Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155 Accessed June 9, 20141
   Google Scholar
• Miller A Dishon S Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status Qual Life Res 2006 15 2 259 271 16468081
   PubMed Web of Science ®Google Scholar
• Rudick RA Miller D Clough JD Gragg LA Farmer RG Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis Arch Neurol 1992 49 12 1237 1242 1449401
   PubMedGoogle Scholar
• Kita M Fox RJ Gold R Effect of BG-12(DMF) on quality of life in patients with MS Presented at the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis 18th Annual Meeting Orlando, FL, USA May 29 to June 1, 2013
   Google Scholar
• Kappos L Gold R Arnold DL Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study Mult Scler 2014 20 2 243 252 24150779
   PubMed Web of Science ®Google Scholar
• Kita M Fox RJ Phillips JT Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study Mult Scler 2014 20 2 253 257 24150778
   PubMed Web of Science ®Google Scholar
• Polman CH Reingold SC Edan G Diagnostic criteria for multiple sclerosis:2005 revisions to the “McDonald Criteria.” Ann Neurol 2005 58 6 840 846 16283615
   PubMed Web of Science ®Google Scholar